Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology

详细信息    查看全文

• 作者：Ai-Di Gu (1) (2)
  Li-Xia Lu (3)
  Yan-Bo Xie (1) (2)
  Li-Zhen Chen (1) (2)
  Qi-Sheng Feng (1) (2)
  Tiebang Kang (1) (2)
  Wei-Hua Jia (1) (2)
  Yi-Xin Zeng (1) (2)
  
• 刊名：Journal of Translational Medicine
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：7
• 期：1
• 全文大小：787KB
• 参考文献：1. Rickinson AB, Kieff E: / Epstein-Barr virus / 4 Edition Philadelphia (Pennsylvania): Lippincott/Williams & Wilkins 2001.
  2. Crawford DH: Biology and disease associations of Epstein-Barr virus. / Philos Trans R Soc Lond B Biol Sci 2001, 356:461-73. CrossRef
  3. Henle G, Henle W, Diehl V: Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. / Proc Natl Acad Sci USA 1968, 59:94-01. CrossRef
  4. Ambinder RF: Epstein-barr virus and hodgkin lymphoma. / Hematology Am Soc Hematol Educ Program 2007, 2007:204-09.
  5. List AF, Greco FA, Vogler LB: Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. / J Clin Oncol 1987, 5:1673-689.
  6. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T: Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. / Proc Natl Acad Sci USA 1994, 91:9131-135. CrossRef
  7. de The G: / Sero epidemiology of EBV and associated malignancies Wymondham: Caister Academic Press 2005.
  8. Tao Q, Young LS, Woodman CB, Murray PG: Epstein-Barr virus (EBV) and its associated human cancers -genetics, epigenetics, pathobiology and novel therapeutics. / Front Biosci 2006, 11:2672-713. CrossRef
  9. Kelly GL, Rickinson AB: Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. / Hematology Am Soc Hematol Educ Program 2007, 2007:277-84.
  10. Aozasa K, Takakuwa T, Hongyo T, Yang WI: Nasal NK/T-cell lymphoma: epidemiology and pathogenesis. / Int J Hematol 2008, 87:110-17. CrossRef
  11. Tsuchiya S: Diagnosis of Epstein-Barr virus-associated diseases. / Crit Rev Oncol Hematol 2002, 44:227-38. CrossRef
  12. Mueller N: Overview: viral agents and cancer. / Environ Health Perspect 1995,103(Suppl 8):259-61. CrossRef
  13. Henle G, Henle W: Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. / Int J Cancer 1976, 17:1-. CrossRef
  14. Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U: Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. / Int J Cancer 1990, 45:1061-064. CrossRef
  15. Feng P, Chan SH, Soo MY, Liu D, Guan M, Ren EC, Hu H: Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis. / Cancer 2001, 92:1872-880. CrossRef
  16. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, Benslimane A, Khyatti M: Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. / J Clin Microbiol 2001, 39:3164-170. CrossRef
  17. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. / N Engl J Med 2001, 345:1877-882. CrossRef
  18. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, / et al.: Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. / Br J Cancer 2007, 96:623-30. CrossRef
  19. Yip TT, Ngan RK, Lau WH, Poon YF, Joab I, Cochet C, Cheng AK: A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. / Cancer 1994, 74:2414-424. CrossRef
  20. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM: Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. / J Infect Dis 2004, 190:53-2. CrossRef
  21. Elshal MF, McCoy JP: Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. / Methods 2006, 38:317-23. CrossRef
  22. Gu AD, Xie YB, Mo HY, Jia WH, Li MY, Li M, Chen LZ, Feng QS, Liu Q, Qian CN, Zeng YX: Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. / J Gen Virol 2008, 89:1152-158. CrossRef
  23. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM: Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. / J Clin Microbiol 2006, 44:1459-467. CrossRef
  24. Tarbouriech N, Buisson M, Geoui T, Daenke S, Cusack S, Burmeister WP: Structural genomics of the Epstein-Barr virus. / Acta Crystallogr D Biol Crystallogr 2006, 62:1276-285. CrossRef
  25. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J, Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX: Evaluation of a multianalyte profiling assay and an enzyme-linked immunosorbent assay for serological examination of Epstein-Barr virus-specific antibody responses in diagnosis of nasopharyngeal carcinoma. / Clin Vaccine Immunol 2008, 15:1684-688. CrossRef
  26. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM: Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. / J Med Virol 2005, 75:593-02. CrossRef
  27. Chow KC, Ma J, Lin LS, Chi KH, Yen SH, Liu SM, Liu WT, Chen WK, Chang TH, Chen KY: Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. / Cancer Epidemiol Biomarkers Prev 1997, 6:363-68.
  28. de-Vathaire F, Sancho-Garnier H, de-The H, Pieddeloup C, Schwaab G, Ho JH, Ellouz R, Micheau C, Cammoun M, Cachin Y, / et al.: Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. / Int J Cancer 1988, 42:176-81. CrossRef
  29. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. / N Engl J Med 2004, 350:2461-470. CrossRef
  30. Lo YM, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, Huang DP: Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. / Cancer Res 2000, 60:2351-355.
  31. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P, / et al.: Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. / Nat Genet 2002, 31:395-99.
  32. Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, Li XL, Hu DX, Tan C, Xiang JJ, Zhou J, / et al.: A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. / Cancer Res 2004, 64:1972-974. CrossRef
  33. Yang XR, Diehl S, Pfeiffer R, Chen CJ, Hsu WL, Dosemeci M, Cheng YJ, Sun B, Goldstein AM, Hildesheim A: Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. / Cancer Epidemiol Biomarkers Prev 2005, 14:900-05. CrossRef
  34. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, Sun B, Hsu MM, Chen IH, Chen JY, / et al.: Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. / Int J Cancer 2004, 111:117-23. CrossRef
  35. Friborg J, Jarrett RF, Liu MY, Falk KI, Koch A, Olsen OR, Duncan P, Wohlfarht J, Chen JY, Melbye M: Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland. / J Med Virol 2007, 79:1877-881. CrossRef
  36. Hildesheim A, Dosemeci M, Chan CC, Chen CJ, Cheng YJ, Hsu MM, Chen IH, Mittl BF, Sun B, Levine PH, / et al.: Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. / Cancer Epidemiol Biomarkers Prev 2001, 10:1145-153.
  37. Yang X, Goldstein AM, Chen CJ, Rabkin CS, Chen JY, Cheng YJ, Hsu WL, Sun B, Diehl SR, Liu MY, / et al.: Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. / Int J Cancer 2006, 118:780-84. CrossRef
  38. Yu MC, Garabrant DH, Huang TB, Henderson BE: Occupational and other non-dietary risk factors for nasopharyngeal carcinoma in Guangzhou, China. / Int J Cancer 1990, 45:1033-039. CrossRef
  39. Yu MC, Yuan JM: Epidemiology of nasopharyngeal carcinoma. / Semin Cancer Biol 2002, 12:421-29. CrossRef
  40. Zheng YM, Tuppin P, Hubert A, Jeannel D, Pan YJ, Zeng Y, de The G: Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China. / Br J Cancer 1994, 69:508-14.
  41. Evans AS, Niederman JC, McCollum RW: Seroepidemiologic studies of infectious mononucleosis with EB virus. / N Engl J Med 1968, 279:1121-127. CrossRef
  42. Bhaduri-McIntosh S, Landry ML, Nikiforow S, Rotenberg M, El-Guindy A, Miller G: Serum IgA antibodies to Epstein-Barr virus (EBV) early lytic antigens are present in primary EBV infection. / J Infect Dis 2007, 195:483-92. CrossRef
  43. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelman J: Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. / N Engl J Med 1989, 320:689-95. CrossRef
  44. Tao Q, Srivastava G, Chan AC, Chung LP, Loke SL, Ho FC: Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. / J Med Virol 1995, 45:71-7. CrossRef
  45. Tao Q, Srivastava G, Dickens P, Ho FC: Detection of Epstein-Barr virus-infected mucosal lymphocytes in nasal polyps. / Am J Pathol 1996, 149:1111-118.
  46. Ng MH, Chan KH, Ng SP, Zong YS: Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma. / Ai Zheng 2006, 25:250-56.
  47. Chang ET, Zheng T, Lennette ET, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE: Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma. / J Infect Dis 2004, 189:2271-281. CrossRef
  48. Ambinder RF: Epstein-Barr virus associated lymphoproliferations in the AIDS setting. / Eur J Cancer 2001, 37:1209-216. CrossRef
  49. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, / et al.: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. / N Engl J Med 1989, 321:1080-085. CrossRef
  
• 作者单位：Ai-Di Gu (1) (2)
  Li-Xia Lu (3)
  Yan-Bo Xie (1) (2)
  Li-Zhen Chen (1) (2)
  Qi-Sheng Feng (1) (2)
  Tiebang Kang (1) (2)
  Wei-Hua Jia (1) (2)
  Yi-Xin Zeng (1) (2)
  
  1. State Key Laboratory of Oncology in Southern China, Guangzhou, PR China
  2. Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, PR China
  3. Department of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, PR China
  

文摘

Background Serological examination of Epstein-Barr virus (EBV) antibodies has been performed for screening nasopharyngeal carcinoma (NPC) and other EBV-associated diseases. Methods By using xMAP technology, we examined immunoglobulin (Ig) A antibodies against Epstein-Barr virus (EBV) VCA-gp125, p18 and IgA/IgG against EA-D, EBNA1 and gp78 in populations with distinct diseases, or with different genetic or geographic background. Sera from Cantonese NPC patients (n = 547) and healthy controls (n = 542), 90 members of high-risk NPC families and 52 non-endemic healthy individuals were tested. Thirty-five of NPC patients were recruited to observe the kinetics of EBV antibody levels during and after treatment. Patients with other EBV-associated diseases were collected, including 16 with infectious mononucleosis, 28 with nasal NK/T cell lymphoma and 14 with Hodgkin's disease. Results Both the sensitivity and specificity of each marker for NPC diagnosis ranged 61-4%, but if combined, they could reach to 84.5% and 92.4%, respectively. Almost half of NPC patients displayed decreased EBV immunoactivities shortly after therapy and tumor recurrence was accompanied with high EBV antibody reactivates. Neither the unaffected members from high-risk NPC families nor non-endemic healthy population showed statistically different EBV antibody levels compared with endemic controls. Moreover, elevated levels of specific antibodies were observed in other EBV-associated diseases, but all were lower than those in NPC. Conclusion Combined EBV serological biomarkers could improve the diagnostic values for NPC. Diverse EBV serological spectrums presented in populations with different EBV-associated diseases, but NPC patients have the highest EBV activity.